TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26208671

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement using telemedical data transmission
Number of subjects: 3102

Group type: COMPARATOR
Intervention: Office Blood Pressure (OBP) measurement
Number of subjects: 3102

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement indicating persistent hypertension
Number of subjects: 3102

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement indicating white coat hypertension (WCH)
Number of subjects: 3102

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurement indicating masked hypertension (MH)
Number of subjects: 3102
Study: 26208810

Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in West Asia
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in Latin America
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in East Asia
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Magnesium levels in adults with metabolic syndrome in Europe/Oceania
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Magnesium levels in high-quality studies
Number of subjects: 5496

Group type: EXPERIMENTAL
Intervention: Magnesium levels in low-quality studies
Number of subjects: 5496
Study: 26208920

Group type: EXPERIMENTAL
Intervention: Ticagrelor and ASA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic clopidogrel and ASA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Branded clopidogrel and ASA
Number of subjects: 0
Study: 26209332

Group type: EXPERIMENTAL
Intervention: Cytokine release measured by IL-6, IL-8, CXCL1, TGF-β and CD40L at 5 different time points during liver transplantation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TEE) and Tissue Doppler Imaging (TDI) monitoring
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postreperfusion syndrome
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Haemodynamic parameters and variations of TEE parameters
Number of subjects: 17
Study: 26210388

Group type: EXPERIMENTAL
Intervention: Loss of control eating (LCE)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Objectively large binge episodes (OBEs)
Number of subjects: 329

Group type: COMPARATOR
Intervention: No loss of control eating
Number of subjects: 329
Study: 26210442

Group type: EXPERIMENTAL
Intervention: Continuous infusion of busulfan over 90 hours
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous infusion of busulfan with intermittent fludarabine
Number of subjects: 54
Study: 26210474

Group type: EXPERIMENTAL
Intervention: NIV in ICU
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: NIV in ED
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: NIV on general wards
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: NIV in other units
Number of subjects: 499
Study: 26210512

Group type: EXPERIMENTAL
Intervention: Probiotic therapy for four weeks in addition to standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 26210682

Group type: EXPERIMENTAL
Intervention: RG7112 with high-fat/high-energy meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RG7112 with new formulation under fasting condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RG7112 with multiple-dose administrations (4 schedules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RG7112 with liquid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose consecutive daily dosing for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose consecutive daily dosing for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly dosing schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose/long-duration (20-day) daily schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum MIC-1 and blood platelet profiles
Number of subjects: 0
Study: 26211987

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.8 mg/kg) administered i.v. on day 1 of a 21-day cycle for a total of 4 cycles
Number of subjects: 37
Study: 26212068

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA methylation and histone deacetylase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miRNA blockade strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor microenvironment targeting
Number of subjects: 0
Study: 26212464

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis disease burden (total joint pain and disease activity)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Mood disturbance (measured by Center for Epidemiological Studies Depression Scale)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Disability (measured by Health Assessment Questionnaire disability index)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Role functioning (measured by Short Form 36 health survey)
Number of subjects: 103
Study: 26212872

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 303
Study: 26213141

Group type: EXPERIMENTAL
Intervention: MK2206 (AKT inhibitor) administered orally at 200 mg once weekly in 28-day cycles up to 12 cycles; final doses included 300 mg (n=33), 250 mg (n=2), 200 mg (n=16), and 135 mg (n=8).
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: MK2206 (AKT inhibitor)
Number of subjects: 59
Study: 26213309

Group type: EXPERIMENTAL
Intervention: CRP level of ≤10 mg/liter and MBDA score of >44
Number of subjects: 347

Group type: COMPARATOR
Intervention: CRP level of >10 mg/liter
Number of subjects: 347
Study: 26213313

Group type: EXPERIMENTAL
Intervention: [(18)F]FDG PET
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: [(18)F]HX4 PET
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: [(18)F]HX4 HV within [(18)F]FDG HV
Number of subjects: 20
Study: 26213360

Group type: EXPERIMENTAL
Intervention: Ultra-staging with ≥12 LNs, H&E-negative LNs, and IHC-negative LNs (pN0i-)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Conventional staging (pN0i+)
Number of subjects: 203
Study: 26213608

Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SCIT) with a standardized allergen extract from Olea europaea; up-dosing doses: 300, 600, 3000, 6000, and 15000SQ+ administered weekly, followed by a maintenance dose of 15000SQ+ after 2 weeks
Number of subjects: 93
Study: 26213798

Group type: EXPERIMENTAL
Intervention: IFN-γ release assay (QFT and T-SPOT.TB)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Skin test
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: IFN-γ release assay-based latent infection prevalence
Number of subjects: 506
Study: 26214043

Group type: EXPERIMENTAL
Intervention: Fourier domain long-range optical coherence tomography (LR-OCT)
Number of subjects: 72
Study: 26214545

Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: shCBT + sibutramine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: shCBT + placebo
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study: 26215720

Group type: EXPERIMENTAL
Intervention: Serum biomarkers of brain ischaemia
Number of subjects: 350

Group type: COMPARATOR
Intervention: Definite diagnosis by a panel of three experienced neurologists
Number of subjects: 350
Study: 26215832

Group type: EXPERIMENTAL
Intervention: TV viewing (2-hour/day increase)
Number of subjects: 221426
Study: 26216294

Group type: EXPERIMENTAL
Intervention: LOXO-101
Number of subjects: 1
Study: 26216360

Group type: EXPERIMENTAL
Intervention: Total specific airway resistance (sRtot)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Forced expiration volume in 1 second (FEV1)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Forced expiration volume in 1 second to forced vital capacity ratio (FEV1/FVC)
Number of subjects: 885
Study: 26216692

Group type: EXPERIMENTAL
Intervention: Ezogabine/retigabine (EZG/RTG)
Number of subjects: 203
Study: 26217225

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) at doses of 0.3, 1, 2, or 3 μg/kg/min infused for 30 min followed by open-label administration for at least 90 min.
Number of subjects: 203
Study: 26217506

Group type: EXPERIMENTAL
Intervention: Integrated obesity management system (preceptorships with a virtual community and on-site coaching)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Clinical practice guidelines (control group)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Integrated obesity management system
Number of subjects: 220
Study: 26217532

Group type: EXPERIMENTAL
Intervention: Promotora-delivered peer support weight loss intervention
Number of subjects: 22
Study: 26217540

Group type: EXPERIMENTAL
Intervention: Standard treatment plus polyglucosamine (ST + PG)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard treatment plus placebo (ST + PL)
Number of subjects: 115
Study: 26217539

Group type: EXPERIMENTAL
Intervention: Intensified Maintenance (continued in-person visits)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard Maintenance (received materials by mail or e-mail)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All participants (during active weight loss phase, months 0-6)
Number of subjects: 79
Study: 26217542

Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vitamin D3 60000 IU
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 26218032

Group type: EXPERIMENTAL
Intervention: Individualized prophylaxis
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Weekly prophylaxis
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Modified prophylaxis
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Episodic treatment
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no inhibitors observed)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 211
Study: 26218540

Group type: EXPERIMENTAL
Intervention: AZD8329 (single oral doses or repeat daily doses for 7-9 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COMPOUND-20 (single oral doses or repeat daily doses for 7-9 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COMPOUND-20 (continuous cover for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human and rat AT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Murine disease models
Number of subjects: 0
Study: 26221138

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (50 mg/d) for 12 weeks
Number of subjects: 13
Study: 26221665

Group type: EXPERIMENTAL
Intervention: Generative probabilistic approach to discover disease subtypes determined by genetic variants.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated data evaluation of the generative method.
Number of subjects: 0
Study: 26222441

Group type: EXPERIMENTAL
Intervention: Subgam (normal immunoglobulin, IgG) given weekly as a rapid subcutaneous infusion
Number of subjects: 50
Study: 26222558

Group type: EXPERIMENTAL
Intervention: PLX3397 (1000 mg per day)
Number of subjects: 23
Study: 26222814

Group type: EXPERIMENTAL
Intervention: Within-breath forced oscillation technique in COPD patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Within-breath respiratory impedance parameters in COPD patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Peak-to-peak impedance (Zpp) in COPD patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Various impedance measures (Zm, Zi, Ze, Zbe, Zpp, ΔZrs) in severe and very severe COPD patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Correlation of respiratory impedance with spirometric indices of airway obstruction
Number of subjects: 114
Study: 26222884

Group type: EXPERIMENTAL
Intervention: Transfusion of 42-day packed red cells
Number of subjects: 18

Group type: COMPARATOR
Intervention: Transfusion of 5-day blood
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Transfusion of aged stored blood
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Transfusion of 42-day-old blood
Number of subjects: 18
Study: 26223436

Group type: EXPERIMENTAL
Intervention: MEDI-575 9 mg/kg/week
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MEDI-575 15 mg/kg/week
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MEDI-575 35 mg/kg/3-weekly
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MEDI-575 25 mg/kg/3-weekly
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MEDI-575
Number of subjects: 22
Study: 26223768

Group type: EXPERIMENTAL
Intervention: Asunaprevir and daclatasvir
Number of subjects: 12
Study: 26223897

Group type: EXPERIMENTAL
Intervention: High AGE diet (4-fold increase)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low AGE diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High AGE diet
Number of subjects: 20
Study: 26224016

Group type: EXPERIMENTAL
Intervention: Mailed invitation to annual skin examination by a general practitioner (GP)
Number of subjects: 3897
Study: 26224101

Group type: EXPERIMENTAL
Intervention: 50 g of parmesan cheese, a boiled egg and 300 ml of water
Number of subjects: 35

Group type: COMPARATOR
Intervention: 500 ml of water
Number of subjects: 35
Study: 26224646

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 9
Study: 26225497

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (normal renal function)
Number of subjects: 40
Study: 26227009

Group type: EXPERIMENTAL
Intervention: Salivary superoxide scavenging activity
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Salivary hydroxyl radical scavenging activity
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Interleukin-1β levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Interleukin-8 levels
Number of subjects: 160
Study: 26227106

Group type: EXPERIMENTAL
Intervention: Alemtuzumab, tacrolimus/MPA with early sirolimus conversion
Number of subjects: 15
Study: 26227192

Group type: EXPERIMENTAL
Intervention: HbA1c levels of 7.1% to 8.0%
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: HbA1c levels of 8.1% to 9.0%
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: HbA1c levels of 9.1% to 10.0%
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: HbA1c levels of >10.0%
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Continuous HbA1c variable
Number of subjects: 764
Study: 26227196

Group type: EXPERIMENTAL
Intervention: Emerging disease-modifying treatments for aortic stenosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive imaging techniques
Number of subjects: 0
Study: 26227782

Group type: EXPERIMENTAL
Intervention: ASCO classification
Number of subjects: 4467
Study: 26228214

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 312
Study: 26228403

Group type: COMPARATOR
Intervention: Ketamine infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26228486

Group type: EXPERIMENTAL
Intervention: 0.03% and 0.06% topical resiquimod gel
Number of subjects: 12
Study: 26228970

Group type: EXPERIMENTAL
Intervention: Exclusive chemoradiotherapy (eCRT)
Number of subjects: 34
Study: 26228971

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (conformal 3D planning or intensity modulated radiotherapy) to a cumulative dose of approximately 40 Gy; systemic therapy maintained unaltered.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Number of subjects: 25
Study: 26229116

Group type: EXPERIMENTAL
Intervention: In vitro and in vivo growth conditions for bacterial species
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex bacterial communities
Number of subjects: 0
Study: 26229965

Group type: EXPERIMENTAL
Intervention: Ballistocardiography (BCG) foil
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ballistocardiography (BCG) foil with quality index
Number of subjects: 22
Study: 26230182

Group type: EXPERIMENTAL
Intervention: Powered exoskeleton-assisted walking
Number of subjects: 8
Study: 26230482

Group type: EXPERIMENTAL
Intervention: Change in somatic depressive symptoms
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Change in cognitive-affective depressive symptoms
Number of subjects: 457
Study: 26230660

Group type: EXPERIMENTAL
Intervention: hsa-miR-16
Number of subjects: 108

Group type: COMPARATOR
Intervention: miRNA profiling (hsa-miR-369-3p, hsa-miR-376a, hsa-miR-376, hsa-miR-411#, hsa-miR-411, mmu-miR-379)
Number of subjects: 108

Group type: COMPARATOR
Intervention: miRNAs in plasma
Number of subjects: 108
Study: 26231011

Group type: EXPERIMENTAL
Intervention: Lower plasma total omega-3 PUFA concentrations
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Higher plasma omega-6:omega-3 PUFA ratios
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Higher arachidonic acid:docosahexaenoic acid, AA:eicosapentaenoic acid, and AA:docosapentaenoic acid ratios
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Plasma PUFAs
Number of subjects: 698

Group type: EXPERIMENTAL
Intervention: Plasma omega-3 fatty acids and omega-6:omega-3 fatty acid ratios
Number of subjects: 698
Study: 26231256

Group type: EXPERIMENTAL
Intervention: Total mismatch patients
Number of subjects: 23
Study: 26231264

Group type: EXPERIMENTAL
Intervention: Children with autism
Number of subjects: 102

Group type: COMPARATOR
Intervention: Serum ferritin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Periodic limb movements in sleep
Number of subjects: 102

Group type: COMPARATOR
Intervention: Polysomnogram parameters
Number of subjects: 102
Study: 26231842

Group type: EXPERIMENTAL
Intervention: Severe LV end-diastolic diameter
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Severe LV mass
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: LV end-diastolic diameter
Number of subjects: 930
Study: 26232340

Group type: EXPERIMENTAL
Intervention: Warfarin treatment
Number of subjects: 12552
Study: 26232910

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 4317

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 4317
Study: 26233552

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) in PSC patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Probe-based confocal laser endomicroscopy (pCLE) in non-PSC patients
Number of subjects: 35
Study: 26234693

Group type: EXPERIMENTAL
Intervention: CDEIS (Crohn's Disease Endoscopic Index of Severity)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SES-CD (Simple Endoscopic Score for Crohn's Disease)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CDEIS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SES-CD large ulcers
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CDEIS deep ulceration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CDEIS ulcerated surface
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SES-CD ulcerated surface
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SES-CD affected surface
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CDEIS and SES-CD total scores
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SES-CD
Number of subjects: 25
Study: 26235360

Group type: EXPERIMENTAL
Intervention: In-office fluoride application recommended to patients aged 6-18 years
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: In-office fluoride application recommended to patients aged over 18 years
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Factors associated with recommending in-office fluoride
Number of subjects: 282
Study: 26235450

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (including vitamin K antagonists and non-vitamin K oral anticoagulants)
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Oral anticoagulant-associated intracerebral hemorrhage
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 1425
Study: 26235613

Group type: EXPERIMENTAL
Intervention: Naproxen/Esomeprazole (NAP/ESO) 500 mg/20 mg given twice daily
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Celecoxib (CEL) 200 mg given once daily
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study: 26235848

Group type: EXPERIMENTAL
Intervention: Radiation therapy (n=48)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No radiation (n=25)
Number of subjects: 73
Study: 26236506

Group type: EXPERIMENTAL
Intervention: Interferon β-1a 44 μg or 22 μg subcutaneously three times weekly
Number of subjects: 334
Study: 26237266

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires of auditory difficulties
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Performance-based tests
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Assessments of speech understanding in noise, binaural processing, temporal resolution, and speech segregation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Overall performance on 10 measures
Number of subjects: 99
Study: 26237356

Group type: EXPERIMENTAL
Intervention: 13-week physical training program
Number of subjects: 18
Study: 26237773

Group type: EXPERIMENTAL
Intervention: Untreated OSA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 26238198

Group type: EXPERIMENTAL
Intervention: Actigraph-GT3X+ accelerometer measuring counts-per-minute (CPM) for physical activity intensity assessment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mixed-regression-model analysis of VO2max percentage and gender
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vector-magnitude (VM) model
Number of subjects: 111
Study: 26238730

Group type: EXPERIMENTAL
Intervention: Experienced group (master/associate master faculty)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Novice group (postgraduate year 4 and 5 residents)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Novice group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Experienced group
Number of subjects: 22
Study: 26238761

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia (C)
Number of subjects: 50